Testing the addition of an anti-cancer drug, berzosertib, to the usual treatment (radiation therapy) for chemotherapy-resistant triple-negative and estrogen and/or progesterone receptor positive, HER2 negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.